BRD2 Emerges as Key Driver of BET Inhibitor Resistance Across Multiple Cancers
核心洞察
A UC Davis study shows cancer cells evade BET inhibitors (搜索) by upregulating BRD2 (搜索) to compensate for BRD4 loss, a resistance mechanism observed across pancreatic, prostate, breast, brain, skin, lung, and blood cancers.
Researchers at the Max Planck Institute reveal that BRD2 (搜索) and BRD4 perform distinct roles in gene activation, with BRD2 acting as an early-stage "stage manager" that organizes transcription machinery before BRD4 drives expression.
BRD2 (搜索)'s unique clustering function is essential for transcription; removing only its clustering domain stalls gene activation as completely as deleting the entire protein.
For over a decade, BET inhibitors (搜索) have been tested in cancer clinical trials with high expectations, yet results have been largely disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond. Now, two independent studies—one from the University of California, Davis and another from the Max Planck Institute of Immunobiology and Epigenetics (搜索) (MPI-IE) in Freiburg—offer converging explanations for these failures and point toward a more precise therapeutic strategy.
The UC Davis team, publishing May 2 in Cellular and Molecular Biology Letters, demonstrated that when BET inhibitors (搜索) eliminate their target protein BRD4, cancer cells compensate by increasing production of a related protein called BRD2 (搜索), which takes over BRD4's epigenetic functions and allows tumors to survive and grow. The MPI-IE study, led by Asifa Akhtar, reveals the molecular basis for why this compensation is so effective: BRD2 and BRD4 perform fundamentally distinct roles in gene activation.
A tale of two BET proteins
The MPI-IE researchers found that BRD4 drives the step most current therapies target—releasing RNA Polymerase II, the enzyme that pushes genes into active transcription. BRD2 (搜索), however, acts earlier at an initiation stage, recruiting and organizing the molecular machinery that gets transcription started in the first place.
"Think of gene activation like stage production. BRD2 (搜索) sets up the stage: assembling the props, costumes and actors to ensure preparations run smoothly. BRD2 then gives BRD4, the actor, the 'start' signal to begin with the performance," said Asifa Akhtar, who led the study at the MPI-IE. "Previous studies had been focused almost entirely on the performance. Our data shows that the setup work happening before is just as critical for gene activation."
Blocking both BRD2 (搜索) and BRD4 simultaneously, as current inhibitors often do, disrupts two different steps of the same process at once and produces effects that are difficult to predict and highly context-dependent.
BRD2 (搜索)'s unique sensitivity to chromatin bookmarks
Part of what makes BRD2 (搜索) distinctive is what it responds to. The enzyme MOF (搜索) places specific chemical tags known as histone acetylations on chromatin, creating a sophisticated labeling system that tells BRD2 where to begin its work. BRD2 is uniquely sensitive to these bookmarks: remove MOF, and BRD2 loses its grip on chromatin, while other BET proteins remain largely unaffected.
"The findings support a model in which acetylated chromatin creates a platform that allows regulatory proteins like BRD2 (搜索) to concentrate and prepare the transcription machinery for when it will be needed," said first author Umut Erdogdu from the Akhtar lab.
Clustering as a functional necessity
Beyond this specificity, BRD2 (搜索) actively organizes the transcription machinery at the spatial level, forming dynamic clusters at gene binding sites that concentrate the necessary molecular components precisely where transcription needs to begin. When the researchers removed only the specific part of BRD2 responsible for forming clusters while leaving the rest of the protein intact, transcription stalled almost as completely as if the entire protein had been deleted.
"This demonstrates that clustering is not a side effect, but a functional feature of transcription regulation. And like a stage manager, BRD2 (搜索) ensures that every performer and every piece of equipment is in place before the curtain rises," said Akhtar.
Resistance across cancer types
The UC Davis study, led by senior author Chang-il Hwang, associate professor of microbiology and molecular genetics and a member of UC Davis Comprehensive Cancer Center (搜索), began when first author Suyakarn (Sonia) Archasappawat noticed an unexpected increase in BRD2 (搜索) expression in RNA sequencing data from pancreatic cancer (搜索) cells treated with a BET inhibitor.
"I was so puzzled, but I thought it might be something that the cells do to adapt and survive under pressure of the treatment," Archasappawat said.
She subsequently analyzed 51 publicly available datasets examining how treatment with JQ1, the most well-studied BET inhibitor, affected gene expression. In all datasets—spanning prostate, breast, brain, skin, gastrointestinal, lung, pediatric, gynecologic, and blood cancers—JQ1 treatment was associated with increased BRD2 (搜索) expression. The team confirmed these findings by treating eight different lab-grown mouse and human cancers with JQ1; in all cases, BRD2 transcription rates increased after treatment.
When the researchers used genetic methods to reduce the cancers' ability to express BRD2 (搜索), the cancers became more susceptible to treatment with JQ1 and other BET inhibitors (搜索). "This shows that BRD2 upregulation contributes to cancer resistance against BET inhibitors," Archasappawat said. "If you close a major highway, the traffic doesn't disappear, it just reroutes. BRD2 is the alternative route that cancer cells use when BRD4 is shut down so that they can survive, proliferate, and eventually metastasize."
Toward a dual-targeting strategy
Both research groups independently conclude that the path forward lies in distinguishing between the distinct roles of BRD2 (搜索) and BRD4. Rather than designing drugs that block the shared chromatin-reading domain across all BET family members, a more promising goal would be to develop therapies that specifically target BRD2 in combination with BRD4 inhibition.
"People have tried to develop BET inhibitor cancer treatments for a long time, but clinical responses have been modest and short-lived because cancers quickly develop resistance," said Hwang. "Understanding how cancer cells adapt and respond to BET inhibition could reveal vulnerabilities and guide more effective therapies."
"Most cancer patients have to undergo multiple rounds of treatment because of drug resistance—it's almost the expected next step—but I don't think it has to be inevitable," Archasappawat added. "If we can identify how cancer cells adapt to resist treatment, we may be able to intercept resistance before it fully locks in."
The UC Davis study was supported by the National Cancer Institute (grant 5R37CA249007), with additional fellowship support from the Anandamahidol Foundation (Thailand) and the UC Davis Comprehensive Cancer Center (搜索) Director's Fellowship.